the aid library

LIST OPTIONS

Filter

3289

Сводное руководство по стратегической информации о вирусных гепатитах. Планирование и мониторинг прогресса на пути к элиминации

World Health OrganizationEurope (2019) C_WHO

В мае 2016 г. Всемирная ассамблея здравоохранения приняла первую Глобальную стратегию сектора здравоохранения (ГССЗ) по проблеме вирусных гепатитов. В ней б...ыла провозглашена цель к 2030 г. добиться элиминации вирусных гепатитов как угрозы общественному здоровью путем реализации (с достаточным уровнем охвата) пяти следующих основных вмешательств: иммунизация против гепатита B; профилактика передачи вируса гепатита B (ВГВ) от матери ребенку; обеспечение безопасности донорской крови и инъекций; принятие мер снижения вреда для людей, употребляющих инъекционные наркотики; предоставление услуг тестирования и лечения. Механизм ВОЗ по мониторингу и оценке в отношении вирусных гепатитов B и C соответствует подходу, ориентированному на результаты, который учитывает такие факторы, как контекст (распространенность инфекции), вкладываемые ресурсы, промежуточные и итоговые результаты (включая каскад мер профилактики, тестирования и лечения) и исходы (заболеваемость и смертность). Системы данных, необходимые для функционирования этого механизма, включают (i) эпиднадзор за ост-рыми гепатитами, случаями хронической инфекции и последствиями;* (ii) оперативные сведения, документирующие меры профилактики, тести-рования и лечения, которые включают каскад услуг медицинской помощи. more

Download (130)

View PDF (137)

Facilitator’s guide: communicating with patients about COVID-19 vaccination

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Download (162)

View PDF (182)

Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases

World Health Organization WHO (2018) C_WHO

Promoting Health - Guide to national implementationof the Shanghai Declaration

World Health Organization WHO (2018) C_WHO

Guide to national implementation of the Shanghai Declaration describes policy orientations and approaches that can unlock the transformative potential of health promotion for sustainable development. This guide was developed to support country level implementation of the commitments and recommendati... more

Facilitator’s guide: communicating with health workers about COVID-19 vaccination

World Health Organization WHO (2021) C_WHO

This guide is designed to accompany the training module, Communicating with health workers about COVID-19 vaccination. It provides detailed explanations, resources and guidance to accompany the slides in the training module and support those implementing the training. It is intended for training fac... more

Download (276)

View PDF (203)

My hero is you 2021 - How kids can fight COVID-19 (Arabic Version)

Inter-Agency Standing Committee IASC; World Health Organization (WHO); UNICEF; et al. (2021) C_WHO

A new story book that aims to help children understand and come to terms with COVID-19 has been produced With the help of a fantasy creature, Ario, “My Hero is You, How kids can fight COVID-19!” explains how children can protect themselves, their families and friends from coronavirus and how to... more

Regional competency assessment tool for midwifery educators and midwives

World Health Organization (WHO), Regional Office for South-East Asia (2021) C_WHO

Оцінка доступності основних лікарських засобів для амбулаторного лікування в Україні

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

WHO recently conducted a survey to assess the availability and cost of a national tracer list of essential medicines in the outpatient sector in Ukraine using a new collection tool – the WHO Essential Medicines and Health Products Price and Availability Monitoring Mobile Application. This tool fac... more

Download (124)

View PDF (291)

Air pollution and child health: prescribing clean air: summary

World Health Organisation (WHO) (2018) C_WHO

This report summarizes the latest scientific knowledge on the links between exposure to air pollution and adverse health effects in children. It is intended to inform and motivate individual and collective action by health care professionals to prevent damage to children’s health from exposure to ... more

External Link

The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises

Watts,N.; N. Amann, M. Arnell, et al. (2020) C1

The Lancet Volume 397, ISSUE 10269, P129-170, January 09, 2021

External Link

A toolkit for national dengue burden estimation

Brady, O. J. et all. WHO (2018) CC

The aim of this toolkit is to guide countries on how to best estimate their current burden of dengue by combining existing data from dengue surveillance systems with on-going research efforts to measure the community burden of dengue.

Download (167)

View PDF (200)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

External Link

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

UN Children's Fund UNICEF (2023) CC

This report makes clear that there is a path to end AIDS. Taking that path will help ensure preparedness to address other pandemic challenges, and advance progress across the Sustainable Development Goals. The data and real-world examples in the report make it very clear what that path is. It is not... more

Download (164)

View PDF (180)

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

Download (249)

View PDF (368)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (289)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

UNAIDS Terminology Guidelines

UNAIDS (2024) CC

Language influences the way we think, how we perceive reality, and how we behave. With respect to HIV, language can embody stigma and discrimination, which impacts access to testing, acquisition of HIV, and engagement with treatment. Language plays a role in supporting respect and empowerment of ind... more

The Interagency Emergency Health Kit 2017
recommended

World Health Organization WHO; UNICEF; ICRC; et al. (2019) C_WHO

Interagency Guidelines; Medicines and medical devices for 10 000 people for approximately three month.

Download (1620)

View PDF (2073)

Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers

World Health Organization WHO (2021) C_WHO

2nd. edition The new edition has been developed to make widely available to programme managers, health care workers in endemic settings, academic researchers, and other key partners, a concise source of information on strategies for MMDP for LF. It is a product of efforts to elaborate and concepts ... more

WHO Guideline on Country Pharmaceutical Pricing Policies

World Health Organization WHO World Health Organization (2020) C_WHO

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov... more

The path that ends AIDS: UNAIDS Global AIDS Update 2023 recommended

The Interagency Emergency Health Kit 2017 recommended

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

The Interagency Emergency Health Kit 2017
recommended